Skip to main content
Yabao Pharmaceutical Group Co.,Ltd logo

Yabao Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 600351 ISIN · CNE000001CM5 LEI · 65560071PKRS4UHMVU53 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,360 across all filing types
Latest filing 2025-09-01 Transaction in Own Shar…
Country CN China
Listing Shanghai Stock Exchange 600351

About Yabao Pharmaceutical Group Co.,Ltd

http://www.yabao.com.cn

Yabao Pharmaceutical Group Co.,Ltd. focuses on the research, development, manufacturing, and commercialization of pharmaceutical products. The company maintains a specialized portfolio across therapeutic areas including pediatrics, cardiovascular health, and endocrinology. Key offerings include traditional Chinese medicines, chemical drugs, and innovative transdermal patches, such as the Dinggui Erqi Patch. The organization operates integrated production bases and research facilities dedicated to advancing drug delivery systems and biotechnological applications. Its business model emphasizes the modernization of traditional therapies alongside the development of conventional pharmaceuticals to address diverse clinical needs.

Recent filings

Filing Released Lang Actions
亚宝药业集团股份有限公司关于以集中竞价交易方式回购股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the progress of a share repurchase program by 亚宝药业集团股份有限公司. It details the number of shares repurchased, the price range, the total amount spent, and compliance with relevant regulations. The document does not contain financial statements or detailed financial analysis but focuses on the update of the company's share buyback activity. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buyback or sale of its own shares.
2025-09-01 Chinese
亚宝药业集团股份有限公司关于SY-005项目新适应症获得临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from 亚宝药业集团股份有限公司 regarding the approval of a new clinical trial indication for their drug SY-005 by the National Medical Products Administration (国家药监局). It details the drug, the new indication, regulatory approval, and associated risks. The document is short (1267 characters) and serves as a notification of regulatory approval rather than a detailed report or financial statement. It does not contain financial data, earnings, or management discussion. It is not a report publication announcement since it is not announcing the release of a report but rather a regulatory approval notice. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement about clinical trial approval.
2025-08-25 Chinese
亚宝药业集团股份有限公司2025年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2025 半年度报告摘要' which translates to '2025 Half-Year Report Summary'. It contains detailed financial data such as total assets, net profit, revenue, and shareholder information for the half-year period. The document explicitly states it is a summary of the half-year report and references the full half-year report for more details. The content includes substantive financial data and analysis for a period shorter than a full fiscal year, consistent with an Interim / Quarterly Report. The document length is 2513 characters, which is relatively short but contains actual financial data, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2025
2025-08-15 Chinese
亚宝药业集团股份有限公司关于召开2025年半年度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling of a 2025 half-year performance explanation meeting (业绩说明会) by 亚宝药业集团股份有限公司. It mentions the date, time, location, and format of the meeting, as well as instructions for investors to participate and ask questions. The document references the company's 2025 half-year report already published on August 16, 2025, but this document itself is not the report or the financial data. It is a notice about the upcoming investor presentation event to discuss the half-year results. The document length is short (1407 characters) and it does not contain financial statements or substantive financial data. Therefore, it is best classified as an Investor Presentation (IP) announcement rather than the report itself or an earnings release. The document is not a transcript but a notice of the event where the company will present and discuss results.
2025-08-15 Chinese
亚宝药业集团股份有限公司2025年半年度报告
Interim / Quarterly Report Classification · 95% confidence The document is titled "亚宝药业集团股份有限公司2025 年半年度报告" which translates to "Yabao Pharmaceutical Group Co., Ltd. 2025 Semi-Annual Report." It covers the period from January 1, 2025 to June 30, 2025, indicating it is a report for a period shorter than a full fiscal year. The content includes detailed financial data, management discussion and analysis, company overview, business operations, and financial indicators. The length is substantial (15,000 characters), and it contains actual financial statements and substantive financial analysis. This matches the definition of an Interim / Quarterly Report (IR). It is not an announcement or a brief summary, nor is it a full annual report (10-K). Therefore, the correct classification is IR with high confidence. H1 2025
2025-08-15 Chinese
亚宝药业集团股份有限公司关于签订中药新药项目技术转让协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 亚宝药业集团股份有限公司 regarding the signing of a technology transfer agreement for a new traditional Chinese medicine drug project. It details the transaction overview, parties involved, the subject of the transfer, payment terms, and potential impacts and risks. There are no financial statements, quarterly or annual results, or audit information. The document is a formal announcement of a corporate transaction (technology transfer agreement) rather than a financial report or regulatory filing about earnings, management changes, or governance. It does not fit categories like Annual Report, Interim Report, Earnings Release, or M&A filings. The closest fitting category is Capital/Financing Update (CAP), as it relates to a significant transaction involving technology transfer and payment milestones, which impacts the company's capital and development pipeline. The document length is under 5,000 characters, but it is not merely announcing the publication of a report; it is the full announcement of the transaction itself. Therefore, the best classification is CAP with high confidence.
2025-08-05 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.